(function(){ var content_array=["

关于勃林格殷格翰<\/b><\/p> \n

勃林格殷格翰致力于研究突破性疗法，旨在变革生命，守护世世代代的健康。作为一家研发驱动的全球领先生物制药企业，公司在医疗需求高度未得到满足的领域通过创新展现价值。勃林格殷格翰自1885年成立以来一直是一家独立的家族企业，始终着眼长远发展。在人用药品、动物保健和生物制药合同生产三大业务领域，全球有超过5.2万名员工服务逾130个地区。更多详情，请访问：www.boehringer-ingelheim.com<\/a><\/p> \n

勃林格殷格翰目标受众通告<\/b><\/p> \n

本新闻稿由位于德国殷格翰的公司总部发布，旨在提供有关我们全球业务的信息。请知悉与已批准产品的批准状态和说明书相关的信息可能因国家而异，我们开展业务的国家可能已经发布该主题的特定新闻稿。<\/p> \n

参考文献<\/p> \n

    \n
  1. Richeldi L., et al<\/i>. Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4B<\/span>, in Patients with Idiopathic Pulmonary Fibrosis: a Phase 2 Trial. Presented at American Thoracic Society (ATS) International Conference Breaking News session on May 16<\/span> 2022.<\/li> \n
  2. Pulmonary Fibrosis Types and Causes. American Lung Association. https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/pulmonary-fibrosis\/introduction\/types-causes-and-risk-factors<\/a>. [Accessed May 2022<\/span>].<\/li> \n
  3. Symptoms. Pulmonary Fibrosis Foundation. https:\/\/www.pulmonaryfibrosis.org\/understanding-pff\/about-pulmonary-fibrosis\/symptoms<\/a>. [Accessed May 2022<\/span>].<\/li> \n
  4. Nalysnyk L., et al<\/i>. Incidence and Prevalence of Idiopathic Pulmonary Fibrosis: Review of the Literature. Eur Respir Rev. 2012;21(126):355-361.<\/li> \n
  5. Data on file. Boehringer Ingelheim. DOF OFEV.RES.IPF\/08\/11January2016. Worldwide Prevalence 2016.<\/li> \n
  6. Other Types of Pulmonary Fibrosis. Pulmonary Fibrosis Foundation. https:\/\/www.pulmonaryfibrosis.org\/understanding-pff\/types-of-pulmonary-fibrosis\/other-types-of-pulmonary-fibrosis<\/a>. [Accessed May 2022<\/span>].<\/li> \n<\/ol>"]; $("#dvExtra").html(content_array[0]);})();